Peptide Companion
Back to catalog
Peptide Companion
single
Anti-Aging
Vial: 10 mg

SS-31 (10 mg Vial)

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome. This educational protocol presents a once‑daily subcutaneous approach using concentrated reconstitution for practical insulin‑syringe measurements.

Dose
Research dosing varies
Frequency
Protocol dependent
Timing
As per research design
Duration
Study specific

Mitochondrial-targeted peptide. Cardioprotective research. Follow specific protocols.

Dosing Schedule
WeekDaily Dose (mg)Units (per injection) (mL)
Weeks 1–25 mg (5000 mcg)50 units (0.50 mL)
Weeks 3–810 mg (10,000 mcg)100 units (1.0 mL)
Supplies Needed
  • •Peptide Vials (SS‑31, 10 mg each):
  • •Insulin Syringes (U‑100, 1 mL capacity):
  • •Bacteriostatic Water (30 mL bottles): Use 1.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • International Journal of Molecular Sciences (MDPI)

    Elamipretide: comprehensive review of structure, mechanism of action, and therapeutic potential

    View source

  • British Journal of Pharmacology (PMC)

    Cardiolipin‑binding mechanism and mitochondrial membrane stabilization by SS‑31

    View source

  • U.S. Food & Drug Administration (FDA)

    FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025)

    View source

  • Journal of the American College of Cardiology (JACC)

    PROGRESS‑HF trial: safety and tolerability of elamipretide in heart failure patients

    View source

  • Neurology (AAN Journals)

    MMPOWER‑2 trial: elamipretide in primary mitochondrial myopathy

    View source

  • Biochimica et Biophysica Acta (BBA) – Bioenergetics

    Cardiolipin remodeling and cristae structure: role in mitochondrial function

    View source

  • Journal of Cardiovascular Pharmacology (PMC)

    SS‑31 reduces oxidative stress and improves mitochondrial bioenergetics

    View source

  • Alzheimer’s Drug Discovery Foundation

    Cognitive Vitality Report: SS‑31 (elamipretide) preclinical and clinical overview

    View source

  • Orphanet Journal of Rare Diseases (PMC)

    Barth syndrome: clinical presentation, diagnosis, and emerging therapies

    View source

  • Centers for Disease Control and Prevention (CDC)

    Vaccine administration: subcutaneous injection technique (angle, site selection, no aspiration)

    View source

  • Johns Hopkins Arthritis Center

    Patient guide: how to give a subcutaneous injection (step‑by‑step instructions)

    View source

  • NCBI Bookshelf (StatPearls)

    Best practices for injection: aseptic technique, preparation, and administration

    View source

  • Pharmacologic Considerations of Subcutaneous Drug Administration (PMC)

    Site rotation, absorption kinetics, and prevention of lipohypertrophy

    View source

Educational content adapted from peptidedosages.com. Not medical advice.